Operating
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital
Pfizer Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital increased by 4711.1% to $1.73B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.7%, from $1.92B to $1.73B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalHigher is better
VolatilityVolatile
First reportedQ1 2015
Last reportedQ1 2026May 5, 2026
How to read this metric
A positive value indicates cash generation through efficient working capital management, while a negative value indicates cash tied up in operations.
Detailed definition
This metric aggregates changes in working capital components, such as accounts receivable, inventory, and accounts payab...
Peer comparison
Highly comparable across all sectors; a key indicator of operational efficiency and cash conversion cycle health.
Metric ID:
operating_increase_decrease_in_operating_capitalHistorical Data
14 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$5.38B | -$6.77B | $730.00M | $2.77B | $4.59B | $5.51B | $3.92B | $1.20B | $3.34B | $3.54B | $1.92B | $4.99B | $36.00M | $1.73B |
| QoQ Change | — | -25.7% | +110.8% | +278.9% | +65.8% | +20.1% | -28.9% | -69.4% | +178.2% | +6.0% | -45.7% | +160.0% | -99.3% | >999% |
| YoY Change | — | — | — | +151.4% | +167.8% | +654.4% | +41.6% | -73.8% | -39.4% | -9.7% | -42.5% | +41.1% | — | -9.7% |
Range-$6.77B – $5.51B
CAGR-29.5%
Avg YoY Growth+88.1%
Median YoY Growth+15.7%
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital at Other Companies
Frequently Asked Questions
- What is Pfizer's adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital?
- Pfizer (PFE) reported adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital of $1.73B in Q1 2026.
- How has Pfizer's adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital changed year-over-year?
- Pfizer's adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital decreased by 9.7% year-over-year, from $1.92B to $1.73B.
- What does adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital mean?
- The net cash impact of changes in day-to-day working capital items.